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ABSTRACT
ObjeCtives
To assess the frequency of fatal recrudescence from 
Ebola virus disease after discharge from treatment 
centres, and explore the influence of infecting dose on 
case fatality rates.
Design
Retrospective cohort study.
setting
Western Area, Sierra Leone.
PartiCiPants
151 survivors treated for Ebola virus disease at the 
Kerry Town treatment centre and discharged. Survivors 
were followed up for a vital status check at four to nine 
months after discharge, and again at six to 13 months 
after discharge. Verbal autopsies were conducted for 
four survivors who had died since discharge (that is, 
late deaths). Survivors still living in Western Area were 
interviewed together with their household members. 
Exposure level to Ebola virus disease was ascertained 
as a proxy of infecting dose, including for those who 
died.
Main OutCOMe Measures
Risks and causes of late death; case fatality rates; 
odds ratios of death from Ebola virus disease by age, 
sex, exposure level, date, occupation, and household 
risk factors.
results
Follow-up information was obtained on all 151 survivors 
of Ebola virus disease, a mean of 10 months after 
discharge. Four deaths occurred after discharge, all 
within six weeks: two probably due to late 
complications, one to prior tuberculosis, and only one 
after apparent full recovery, giving a maximum 
estimate of recrudescence leading to death of 0.7%. 
In these households, 395 people were reported to have 
had Ebola virus disease, of whom 227 died. A further 
53 people fulfilled the case definition for probable 
disease, of whom 11 died. Therefore, the case fatality 
rate was 57.5% (227/395) for reported Ebola virus 
disease, or 53.1% (238/448) including probable 
disease. Case fatality rates were higher in children 
aged under 2 years and adults older than 30 years, in 
larger households, and in infections occurring earlier 
in the epidemic in Sierra Leone. There was no 
consistent trend of case fatality rate with exposure 
level, although increasing exposure increased the risk 
of Ebola virus disease.
COnClusiOns
In this study of survivors in Western Area, Sierra Leone, 
late recrudescence of severe Ebola virus disease 
appears to be rare. There was no evidence for an effect 
of infecting dose (as measured by exposure level) on 
the severity of disease.
Introduction
Understanding who dies from Ebola virus disease is 
crucial for determining the effect of interventions and 
planning the public health response. The case fatality 
rate for the disease is high but estimates have varied 
between outbreaks and in reports describing the west 
African outbreak. In previous outbreaks, case fatality 
rates have been between 34% and 88%, with generally 
lower rates for the Sudan and Bundibugyo ebolavirus 
species than for Zaire ebolavirus.1-3 In the west African 
outbreak of Zaire ebolavirus, the case fatality rate based 
on the notification data for certain and probable cases 
was 65%, slightly lower in Guinea and higher in Liberia 
than in Sierra Leone, but some cases may not have been 
notified.4  Estimates from west African treatment cen-
tres have ranged from 31%5  to more than 70%,6  but 
patients who die or recover without reaching the cen-
tres are not included and variation reflects admission 
policies and delays, and patient mix as well as care. 
Community level data should give the best estimates 
but there are few such studies,7 8 and to ensure unbi-
ased estimates they would need to include any unre-
ported mild cases and assessment of any unreported 
deaths.
Late deaths due to Ebola complications or recrudes-
cence of the virus would also be excluded from esti-
mated case fatality rates. The recrudescence of Ebola 
virus disease in a nurse in the United Kingdom, nine 
months after the original episode, raised the possibility 
that similar events are occurring but are being missed 
in west Africa, where they might be fatal.9  In Liberia, 
WhAT IS AlReAdy knoWn on ThIS TopIC
Understanding who dies from Ebola virus disease, and when, is crucial for 
determining the effect of interventions and planning the public health response
Case fatality rates vary by age and viral load on admission to treatment centres, but 
it is not known if they vary by infecting dose
Frequency of recrudescence and late deaths from Ebola virus disease after 
discharge from treatment centres is unknown
WhAT ThIS STudy AddS
This is the first cohort study of Ebola virus disease with active follow-up for late 
deaths, and the first large community based study to investigate risk factors for 
death from the disease
Recrudescence of severe Ebola virus disease appears to be rare up to 10 months 
after discharge
Infecting dose, as measured by extent of exposure to body fluids, strongly 
correlated with risk of developing the disease, but there was no consistent trend 
with case fatality rate
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a nine year old child was readmitted with meningoen-
cephalitis and a polymerase chain reaction (PCR) test 
that was positive for Ebola virus one day after discharge 
with negative blood tests.9  Recrudescences are import-
ant not only for the individuals but also as a possible 
source of further outbreaks. The frequency of severe 
recrudescence leading to late deaths is not known, 
although it has been noted that the virus can persist in 
protected body sites for at least nine months.10  Studies 
of post-Ebola sequelae have so far concentrated on sur-
vivors attending clinics,11 12  or have not managed to con-
tact all survivors:13 unless intensive follow-up is 
conducted, deaths could be missed.
Several studies have looked at risk factors for death 
from Ebola virus disease. There is a clear association 
with age in the larger studies, with the lowest case fatal-
ity rates in children aged over 4 years and high rates in 
children aged under 2 years and older adults, and little 
difference by sex.2 4  Some studies have found case fatal-
ity rates decreased over the course of an outbreak,2 8 
perhaps reflecting improved care. Survival in those in 
treatment centres is better than overall survival,8 14  but 
whether this reflects the treatment or the selection of 
those surviving long enough to get to centres is not 
clear. Among patients in the treatment centres, the key 
clinical predictor of mortality is the estimated viral load 
on arrival.14-16
In the first known Ebola outbreak, in Yambuku, Dem-
ocratic Republic of Congo, case fatality rates were 
higher in patients who acquired the infection following 
injection (100%, 85/85) than by contact (80%, 119/149, 
P<0.001).17  This comparison was not adjusted for other 
factors but the age distribution of patients infected by 
injection and by contact was similar.17  The association 
between route of infection and mortality, and the strong 
correlation between viral load on admission to treat-
ment centres and mortality, suggest an effect of infect-
ing dose on severity of disease—as found, for example, 
for measles.18 A dose effect could also explain the lower 
case fatality rate in older children, if they are less 
exposed. The effect of infectious dose on severity of dis-
ease has not been investigated previously for Ebola 
virus disease.
In this retrospective cohort study, we assess risk fac-
tors for death from Ebola virus disease, including level 
of exposure to individuals with Ebola virus disease and 
their body fluids as a proxy of infecting dose. We also 
assess the frequency of late deaths in those patients dis-
charged as survivors.
Methods
As part of a retrospective cohort study of transmission 
patterns, all survivors (or their parents or guardians) 
who were discharged from the Kerry Town Ebola treat-
ment centre between November 2014 and March 2015 
were sought and asked to attend an interview, together 
with anyone who was living with them at the time that 
anyone in their household had Ebola virus disease. All 
the people living in the household at that time were 
enumerated, and their age, sex, and whether they had 
had or died from Ebola virus disease was recorded. 
For  those household members who were not said to 
have had Ebola virus disease, we asked about symp-
toms at that time. For those discharged as survivors fol-
lowing negative PCR tests for the virus, but who were 
subsequently found to have died, a verbal autopsy with 
family members was conducted by a physician, and we 
examined medical notes and sought information from 
the treating physicians, where available. The verbal 
autopsies used a modified version of the World Health 
Organization’s 2014 verbal autopsy instrument. House-
holds were sought for interview between June and Sep-
tember 2015, and again between December 2015 and 
January 2016 to confirm vital status and conduct verbal 
autopsies. Individual, written informed consent was 
sought before interviews, with consent from parents or 
guardians for those aged under 18 years.
To estimate the level of exposure to Ebola virus, we 
asked household members to describe in their own 
words what happened when the Ebola infection struck. 
For each person with Ebola virus disease, we asked 
what symptoms they had had, who had taken care of 
them, who helped them with different activities, who 
shared a bed with them, among other details. We also 
asked about any external contacts. The aim was to iden-
tify the extent of contact with possibly infective body 
fluids. Using an eight level scale, we assigned the max-
imum contact level for each person in the household. 
We predefined this scale on the basis of the available 
literature and in discussion with frontline health work-
ers working with individuals with Ebola virus disease. 
Exposure, from the highest to lowest levels, was defined 
as follows:
•	 Direct contact with, or touching, the body of a person 
who died of Ebola virus disease
•	 Direct contact with the body fluids of a patient who 
has Ebola virus disease with wet symptoms (that is, 
diarrhoea, vomiting, or bleeding)
•	 Direct contact with a patient with wet symptoms (eg, 
sharing a bed, providing care, embracing, carrying)
•	 Direct contact with a patient with dry symptoms (that 
is, without wet symptoms)
•	 Indirect contact with a patient with wet symptoms 
(eg, washing their clothes)
•	 Indirect contact with a patient with dry symptoms
•	 Minimal contact (eg, shared meals)
•	 No known contact
We defined individuals with Ebola virus disease as 
those already known as survivors from the Kerry Town 
treatment centre, reported by their families to be survi-
vors from other treatment centres, or reported to have 
died of the disease. In addition, we included individu-
als (living or dead) not reported as having had Ebola 
virus disease but who had symptoms fitting the Sierra 
Leone case definition of probable disease,19 unless they 
had had a negative PCR test at the time. We assessed the 
effect of including people with probable disease in a 
sensitivity analysis. Recrudescence of Ebola virus dis-
ease was defined as illness or death that could not be 
attributed to a non-Ebola related cause after a period of 
full recovery from confirmed Ebola virus disease.
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Analyses of risk factors for death used multiple logis-
tic regression, adjusting for clustering by household 
using random effects. In addition to age, sex, and expo-
sure level, we assessed other risk factors for associa-
tions with the outcome of Ebola virus disease. These 
factors included first or subsequent case in the house-
hold, date of Ebola virus infection in household, posi-
tion in household (head or member), occupation, 
number of people in the household, and household 
living conditions (as a score based on measures of 
crowding and sanitation (access to water, soap, and 
latrine)). Age, sex, and exposure level were kept in the 
multivariable model a priori. We added other variables 
one by one and retained them in the model if they were 
associated with mortality. We repeated the analyses 
excluding those cases and deaths classified as probable 
Ebola virus disease but not reported as Ebola virus dis-
ease by the family. We used Stata 14 for analysis.
Patient involvement
Two survivors of Ebola virus disease were involved in 
the development of the questionnaire and the imple-
mentation of the study and were asked to advise on 
interpretation and writing up of results. There are no 
plans to disseminate the results of the research directly 
to the study participants or the relevant patient commu-
nity, but we will disseminate results to the Ministry of 
Health and Sanitation and the Ministry of Social Wel-
fare, Gender and Children’s Affairs in Sierra Leone, who 
have responsibility for Ebola survivors.
Results
late deaths
We obtained follow-up information on all 151 survivors 
who had been discharged from the Kerry Town Ebola 
treatment centre with negative blood tests, either from 
direct contact, or from families or other informants. 
Four of these survivors had died. The others were 
known to be alive for a mean of 10 months (range six to 
13) after discharge. Details of the four late deaths are as 
follows:
•	 Patient A: a 25 year old woman who died 15 days after 
discharge. During admission, she showed signs of 
hepatitis. Her liver function tests had greatly 
improved before discharge but her amylase level was 
very high. At discharge, her family reported that she 
was unable to walk but could crawl. She “felt fine” for 
two days but then developed abdominal swelling, 
diarrhoea, and swelling of the legs and face, and she 
looked pale and jaundiced. A postmortem swab by 
the burial team was found to be negative for Ebola 
virus by PCR.
•	 Patient B: a 32 year old woman who died one day after 
discharge. She was very confused on admission, then 
improved but continued to act strangely. She had 
high blood pressure on some days but not consis-
tently. Her platelet count was normal. At discharge, 
she was unable to walk. The following day, she had a 
sudden severe headache and was unable to talk or 
use her limbs. She died that evening. A postmortem 
swab by the burial team was found to be negative for 
Ebola virus by PCR.
•	 Patient C: a 17 year old boy who died five weeks after 
discharge. His health was reported to have returned 
to normal after discharge. He then developed weight 
loss, night sweats, and a productive cough that 
started after discharge. One week before death, he 
had pain and difficulty swallowing solids but no 
other specific symptoms. He died in his sleep. A post-
mortem swab by the burial team was found to be neg-
ative for Ebola virus by PCR.
•	 Patient D: a 6 year old boy who died one week after 
discharge. He had had a cough for several months 
before having Ebola virus disease. On recovery, he 
remained short of breath with a productive cough 
and fluctuating pyrexia that did not respond to anti-
biotics. He was transferred to a paediatric hospital for 
investigation of possible tuberculosis. A chest radio-
graph was compatible with miliary tuberculosis. A 
postmortem PCR test was borderline positive for 
Ebola virus.
Household members
Of the 151 Kerry Town survivors sought for interview in 
June to September 2015, eight were living outside West-
ern Area. We did not seek to interview households of 
survivors known to have died after discharge, except for 
patient A (because there was another survivor in the 
household). One survivor refused to take part and 16 
were unavailable or not contactable at that time. There-
fore, the remaining 123 survivors (including patient A) 
were included in the study. 
The 123 survivors lived in 94 households with 816 
household members. We excluded four household 
members whose cause of death was unclear (fig 1). 
Overall, 395 people were reported to have had Ebola 
virus disease in these households (including patients 
treated at other facilities), of whom 227 died (excluding 
patient A). A further 53 people fulfilled the case defini-
tion for probable Ebola virus disease, of whom 11 died. 
Therefore, the case fatality rate was 57.5% (227/395) for 
reported Ebola virus disease, or 53.1% (238/448) includ-
ing probable disease.
Figure 2  shows the case fatality rate by age, and table 
1 shows the associations with death among individuals 
with Ebola virus disease. The case fatality rate was 
highest in children under 2 years old and older adults, 
and lowest at ages 10 to 14 years. The case fatality rate 
was higher in larger households, with little difference 
by sex, and varied by exposure level, occupation group, 
time period, and position in household.
In the full multivariable analysis, only age, house-
hold size, date, occupation, and exposure level were 
associated with death (table 2 ). Results were similar in 
a sensitivity analysis after excluding probable disease 
(table 2 ). Despite variation in the outcome by exposure 
level, there was no consistent trend with increasing 
exposure. For comparison, figure 3 shows the associa-
tion of exposure level with risk of Ebola virus disease 
among household contacts (excluding primary cases) 
in these households.
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discussion
Principal findings
In this study, we identified four survivors of Ebola virus 
disease who died after discharge. All four late deaths 
could have been caused by Ebola virus disease and its 
sequelae, although only one patient had a positive PCR 
result in the postmortem swab. Patient A might have 
had pancreatitis as a direct effect of the Ebola virus dis-
ease.20  Patient B appears to have had a stroke.21 Patient 
C could have had an unrelated chest infection, perhaps 
tuberculosis, although the duration was short. Patient 
D could have died of tuberculosis and with, rather than 
of, Ebola virus disease. If all these deaths were due to 
Ebola virus disease, this would give a risk of late death 
of 2.6% (four of 151), but only patient C could be consid-
ered a recrudescence because only he had a period of 
full recovery and so fulfilled the case definition. How-
ever, patient C had a negative PCR result postmortem. 
Bearing in mind the limitations of assigning cause of 
death by verbal autopsy, particularly with non-medical 
informants, this would give a maximum estimate of 
0.7% recrudescence within a mean follow-up of 10 
months.
Among the individuals with Ebola virus disease in 
this study, we found a U shaped pattern of death by age 
with a high case fatality rate in the youngest and oldest 
age groups. We found no association with household 
level socioeconomic factors other than number of peo-
ple in the household. The date of Ebola virus infection 
in the household strongly correlated with mortality. 
Earlier cases of the disease occurred at the height of the 
epidemic in Sierra Leone when services were most 
stretched. By mid-January, case numbers had fallen 
considerably,4 treatment centre beds had increased, 
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Fig 2 | Case fatality rates by age among people with ebola 
virus disease
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Fig 1 | Flow diagram showing study composition of participants, from households of survivors of ebola virus disease
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and staff members were more experienced. The varia-
tion by occupation group might reflect the benefits of 
prompter action, if some groups were more reluctant to 
seek admission. The non-manual group included 10 
religious leaders and chiefs, who all died. Place of resi-
dence had no effect on mortality, but was not a good 
proxy for access to treatment centres because availabil-
ity of places at different centres varied over time, and 
household members were often sent to different treat-
ment centres.
table 1 | univariable associations between individual level and household level factors and mortality among individuals 
with ebola virus disease
no of  
deaths/cases
Proportion 
(%)
Odds ratio (95% Ci) adjusted 
for clustering, age, and sex P
age (years)
<2 20/25 80.0 7.5 (2.3 to 24.2)
<0.001
2-4 16 /33 48.5 1.9 (0.78 to 4.7)
5-9 15/41 36.6 1.1 (0.47 to 2.5)
10-14 11/37 29.7 0.75 (0.30 to 1.9)
15-19 15/44 34.1 1.0 (0.44 to 2.4)
20-29 31/90 34.4 1
30-39 48/77 62.3 3.7 (1.8 to 7.6)
40-49 33/45 73.3 5.8 (2.4 to 13.8)
≥50 46/53 86.8 15.9 (5.9 to 42.7)
sex
Female 135/263 51.3 1
0.82
Male 103/185 55.7 1.1 (0.67 to 1.7)
Primary case
Yes 61/97 62.9 1
0.10
No 177/351 50.4 0.58 (0.30 to 1.1)
exposure level†
Corpse 39/69 56.5 1
0.009
Fluid 30/80 37.5 0.44 (0.19 to 1.0)
Direct wet 89/163 54.6 1.7 (0.79 to 3.6)
Direct dry 37/56 66.1 2.2 (0.89 to 5.5)
Indirect wet 4/11 36.4 0.80 (0.16 to 3.9)
Indirect dry 18/24 75.0 2.1 (0.58 to 7.4)
Minimal/none 21/40 52.5 1.2 (0.45 to 3.3)
Month of illness
November 43/63 68.3 1
0.11 
December 152/297 51.2 0.45 (0.19 to 1.1)
January 31/55 56.4 0.67 (0.23 to 2.0)
February/March 12/33 36.4 0.24 (0.067 to 0.83)
Position in household
Head 34/56 60.7 1
0.03
Member 204/392 52.0 2.4 (1.1 to 5.6)
Occupation
Manual 91/168 54.2 1
0.005*
Non-manual 34/44 77.3 4.3 (1.6 to 11.6)
Healthcare worker 18/22 81.8 4.2 (1.0 to 17.9)
Child/student 89/202 44.1 1.9 (0.76 to 4.8)
Unknown 6/12 50.0 0.52 (0.096 to 2.8)
Household size (no of people)
1-5 6/23 26.1 1
<0.001
6-10 68/163 41.7 1.9 (0.62 to 5.7)
11-15 66/129 51.2 2.6 (0.87 to 8.0)
≥16 98/133 73.7 7.4 (2.4 to 23.1)
living conditions‡
Low 29/67 43.3 1 0.56
Medium 14/251 57.4 1.6 (0.69 to 3.5)
High 64/127 50.4 1.3 (0.56 to 3.2)
area of residence
Rural 54/97 55.7 1
0.60 
Urban 183/348 52.6 0.83 (0.41 to 1.7)
*Excluding unknown category. 
†Corpse=direct contact with body of a person who died of Ebola virus disease; fluid=direct contact with body fluids of patient with wet symptoms; direct 
wet=direct contact with patient with wet symptoms; direct dry=direct contact with patient with dry symptoms; indirect wet=indirect contact with patient 
with wet symptoms; indirect dry=indirect contact with patient with dry symptoms; minimal/none=minimal or no known contact.
‡Household living conditions based on measures of crowding and sanitation (access to water, soap, and latrine). Possible scores were 0-10. More than 
half the population had scores of 6 or 7. Low was taken as <6, medium 6-7, high >7.
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We found no evidence of a consistent association 
between case fatality and the extent of exposure to body 
fluids. Given the strong correlation between these mea-
sured exposure levels and risk of Ebola virus disease 
(fig 3), our predefined exposure scale seemed to be a 
reasonable measure of infecting dose.
strengths and limitations of the study
This large study had a complete follow-up at six to 13 
months after discharge, so late deaths will not have 
been missed. The case fatality rate in this study under-
estimated the overall case fatality rate, because our 
starting point was survivor households (because they 
could be approached through the treatment centre out-
reach team). Excluding one index survivor per house-
hold would give a case fatality rate of 75% (227/301) for 
reported Ebola virus disease, or a rate of 67% (238/354) 
including probable disease. 
We did not include households in which all individu-
als with Ebola virus disease died; therefore, small 
households could have been under-represented in our 
sample. This exclusion might partly explain the associ-
ation found between case fatality rate and household 
size, but it is also possible that large households with 
many affected members found it particularly difficult to 
provide care. 
Associations between the other risk factors and death 
should not be biased. We were able to include probable 
cases and deaths that might have been missed from 
notification data, and assess their influence on the 
results. In our study, inclusion of probable disease low-
ered the case fatality rate, but had little effect on the 
table 2 | Multivariable analysis of association between individual and household level factors and mortality among 
individuals with ebola virus disease, overall and after excluding probable disease
all cases all cases excluding probable disease
Odds ratio (95%Ci)* P Odds ratio (95%Ci)* P
age (years)
<2 10.2 (2.5 to 41.0)
<0.001
8.0 (1.7 to 37.3)
<0.001
2-4 1.3 (0.42 to 3.8) 1.4 (0.41 to 4.9)
5-9 0.92 (0.31 to 2.8) 1.2 (0.39 to 4.0)
10-14 0.70 (0.22 to 2.2) 0.74 (0.23 to 2.4)
15-19 1.1 (0.40 to 3.0) 0.87 (0.30 to 2.5)
20-29 1 1
30-39 4.1 (1.9 to 9.0) 3.7 (1.6 to 8.1)
40-49 6.1 (2.4 to 15.6) 5.1 (2.0 to 13.5)
≥50 10.1 (3.6 to 28.4) 8.4 (3.0 to 23.6)
sex
Female 1
0.80
1
0.44
Male 1.1 (0.67 to 1.7) 1.2 (0.74 to 2.0)
exposure level†
Corpse 1
0.01
1
0.01
Fluid 0.38 (0.16 to 0.89) 0.46 (0.19 to 1.1)
Direct wet 1.1 (0.52 to 2.4) 1.3 (0.60 to 2.6)
Direct dry 2.1 (0.83 to 5.0) 2.7 (1.1 to 7.0)
Indirect wet 0.48 (0.096 to 2.4) 0.52 (0.10 to 2.6)
Indirect dry 1.2 (0.33 to 4.2) 2.1 (0.44 to 9.9)
Minimal/none 1.2 (0.44 to 3.2) 1.2 (0.43 to 3.3)
Month of illness
November 1
0.04
1
0.01
December 0.65 (0.30 to 1.4) 0.48 (0.21 to 1.1)
January 1.2 (0.44 to 3.3) 0.69 (0.23 to 2.0)
February/March 0.21 (0.064 to 0.72) 0.14 (0.041 to 0.49)
Occupation
Manual 1
0.04‡
1
0.07‡
Non-manual 2.7 (1.0 to 7.2) 2.8 (1.1 to 7.5)
Child/student 1.4 (0.55 to 3.5) 1.6 (0.64 to 4.2)
Healthcare worker 5.2 (1.1 to 25.2) 3.8 (0.79 to 18.4)
Unknown 1.4 (0.20 to 10.4) 0.59 (0.070 to 5.1)
Household size (no of people)
1-5 1
0.003
1
<0.001
6-10 2.1 (0.63 to 7.1) 2.4 (0.71 to 7.9)
11-15 3.1 (0.93 to 10.4) 3.6 (1.1 to 12.2)
≥16 7.0 (2.0 to 24.5) 8.4 (2.4 to 29.2)
*Odds ratios adjusted for all other factors in the table.
†Corpse=direct contact with body of a person who died of Ebola virus disease; fluid=direct contact with body fluids of patient with wet symptoms; direct 
wet=direct contact with patient with wet symptoms; direct dry=direct contact with patient with dry symptoms; indirect wet=indirect contact with patient 
with wet symptoms; indirect dry=indirect contact with patient with dry symptoms; minimal/none=minimal or no known contact.
‡Excluding unknown category.
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associations with mortality. We did not know which of 
the deaths occurred in treatment centres, so could not 
assess the benefit of admission directly.
Comparison with other studies
To our knowledge, this is the first cohort study of Ebola 
virus disease with active follow-up for late deaths, and 
the first large community based study to look at risk fac-
tors for death from the disease. Previous studies of 
sequelae have reported on patients seen in clinics so 
would have missed any deaths.11 13
The U shaped pattern of death by age was similar to 
that seen in the WHO notification data4  and, as in these 
notification data,4  we found a marginally higher case 
fatality rate in males. The lack of association between 
socioeconomic status and case fatality suggests that 
although socioeconomic status has been associated 
with the risk of individuals having Ebola virus disease,22 
once ill, living conditions had little effect on the out-
come. The variation in case fatality rate by occupation 
group could reflect different responses to illness; delays 
in coming forward for treatment by healthcare workers 
have been reported previously.23
This study also looks at the association between 
exposure level (as a proxy of dose) and case fatality rate 
in Ebola virus disease. A lack of association between 
infecting dose and severity of disease suggests that 
symptomatic illness can be established by one or very 
few organisms.24  Dose can therefore affect the probabil-
ity of contracting disease without influencing severity 
and risk of death once a person becomes ill. This is con-
sistent with animal challenge studies which find that 
animals receiving low doses of Ebola virus either died 
or remained asymptomatic,25 26  although higher doses 
were associated with a shorter time to death.27  It is also 
compatible with the association between Ebola viral 
load on admission to treatment centres and outcome, 
since a high viral load at this stage suggests a failure to 
control viral multiplication rather than a high initial 
infecting dose. However, deep sequencing of viruses 
has found the same minority variants in different 
patients, suggesting that the transmission bottleneck 
allows through more than one virus.28 29  Whatever the 
mechanism, it appears that once a person becomes ill, 
factors other than infectious dose determine the out-
come, and different immune responses have been noted 
in survivors and fatalities from early on in the disease.30
Conclusions and policy implications
The age pattern of the case fatality rate suggests that 
differences in susceptibility are important in determin-
ing the outcome of Ebola virus disease. However, the 
associations with time period, occupation, and house-
hold size suggest that care given was crucial in reducing 
mortality, emphasising the importance of Ebola treat-
ment centres. Infecting dose of the virus did not appear 
to have a role. All deaths after discharge occurred 
within a few weeks, and we have follow-up information 
six to 13 months later on all survivors. Recrudescence of 
severe active disease leading to death appears to be 
rare, which should be reassuring for Ebola survivors 
and their contacts, but does not remove the need for 
continued monitoring of survivors’ health.
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Fig 3 | relation of exposure level with risk of ebola virus 
disease and with case fatality rate. to assess risk of disease 
by exposure level, primary cases in each household were 
excluded. Probable ebola virus disease and deaths are 
included. Corpse=direct contact with body of a person who 
died of ebola virus disease; fluid=direct contact with body 
fluids of patient with wet symptoms; direct wet=direct 
contact with patient with wet symptoms; direct dry=direct 
contact with patient with dry symptoms; indirect 
wet=indirect contact with patient with wet symptoms; 
indirect dry=indirect contact with patient with dry 
symptoms; minimal/none=minimal or no known contact
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